Discover 1,670 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,670
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
for
Ras-mutated Metastatic Colorectal Cancer, mCRC,
Location: New Brunswick NJ, Florham Park NJ, Canton OH,
Sponsor: Oncolytics Biotech
Sex: All
Age: 18+
Code: NCT07446322
Phase 2, Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
for
Gastric Adenocarcinoma,
Location: New Brunswick NJ, Basking Ridge NJ, Middletown NJ,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT07001748
Phase 2, Phase 3, Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: New Brunswick NJ, Basking Ridge NJ, Middletown NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06672146
Phase 2, Recruiting
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
for
Extensive Stage Lung Small Cell Cancer
Location: New Brunswick NJ, Philadelphia PA, Morristown NJ,
Sponsor: PrECOG, LLC.
Sex: All
Age: 18+
Code: NCT07057791
Phase 2, Recruiting
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: New Brunswick NJ, Willow Grove PA, Livingston NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07195734
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
for
Colorectal Cancer
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Criterium, Inc.
Sex: All
Age: 18+
Code: NCT06992258
Phase 2, Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
for
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Location: New Brunswick NJ, Philadelphia PA, Atlanta GA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 2 - 18
Code: NCT06934967
Phase 3, Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
for
Squamous Cell Carcinoma of Head and Neck
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07276399
Phase 3, Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
for
Neoplasm Malignant
Location: New Brunswick NJ, Baltimore MD, Fairfax VA, Ottawa,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07209111
Phase 2, Recruiting
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
for
Lung Neoplasms
Location: New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 50 - 70+
Code: NCT07165691
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
for
Locally Advanced Urothelial Carcinoma,
Location: New Brunswick NJ, Somerville NJ, Livingston NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06524544
Phase 3, Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Cancer, PDAC,
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07252232
Phase 3, Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Location: New Brunswick NJ, Morristown NJ, New York NY,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT04913285
Phase 1, Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
for
Bladder Cancer, Urinary Bladder Neoplasms
Location: New Brunswick NJ, Quebec, Myrtle Beach SC
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07222488
Phase 1, Phase 2, Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
for
Breast Neoplasms
Location: Livingston NJ, Long Branch NJ, New Brunswick NJ,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07173751
Phase 3, Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
for
Buccal Mucosa Squamous Cell Carcinoma,
Location: New Brunswick NJ, Basking Ridge NJ, Middletown NJ,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT04333537
Phase 2, Phase 3, Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: New Brunswick NJ, Philadelphia PA, Bethlehem PA,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase 2, Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
for
Metastatic Clear Cell Renal Cell Carcinoma,
Location: New Brunswick NJ, New York NY, New Haven CT,
Sponsor: Arcus Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07011719
Phase 3, Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
for
Malignant Neoplasm
Location: New Brunswick NJ, Philadelphia PA, New York NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 0 - 17
Code: NCT07630974
Phase 1, Phase 2, Recruiting
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
for
Endometrial Cancer
Location: New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey